Caplyta (lumateperone) was approved for the treatment of schizophrenia in 2019 and for depressive episodes linked to bipolar I or bipolar II disorder (bipolar depression) in 2021. Caplyta can be used ...
When the results of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) were published in 2005, researchers presented clinicians with a surprise: Doctors had thought that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results